NCT01058239View on ClinicalTrials.gov

Bortezomib Plus Rituximab for EBV+ PTLD

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

November 30, 2017

Conditions
Post-transplant Lymphoproliferative DiseaseSolid Organ TransplantStem Cell Transplant (Bone Marrow Transplant)Epstein Barr Virus Infections
Interventions
DRUG

bortezomib

Given intravenously on days 1, 4, 8 and 11 of every cycle

DRUG

rituximab

given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER